Combination therapy targets resistant breast cancer
NCT ID NCT00317720
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial investigates whether adding everolimus (RAD001) to trastuzumab (Herceptin) can help people with a specific type of advanced breast cancer that has stopped responding to trastuzumab alone. The study includes people with HER2-positive, PTEN-deficient metastatic breast cancer. The goal is to find the best dose of everolimus and to see if the combination can shrink tumors or stop them from growing for at least six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab (Herceptin) and everolimus (RAD001)
What this could lead to
If it works, this combination could offer a new treatment option for people with a specific type of breast cancer that has stopped responding to standard therapy.
What could go wrong
This is an early-phase trial with a small number of participants. The combination may cause significant side effects, and the benefit may not be confirmed in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- NIR Device for Breast Flap Perfusion Study (NCT07680296)
- Long-Term Heart Effects of Anthracycline in Brea NCT07680855
- AMPLIFI: Web-Based Lifestyle Program for Cancer NCT04000880
- Cognitive Stimulation for Elderly Breast Cancer NCT04261153
- TIBEC Trial: Tislelizumab Combo for Advanced Tum NCT07681297
- Cognitive difficulties after breast cancer: feas NCT04213365
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States